Fairfield Bush & Company increased Amazon.Com Inc. (AMZN) stake by 2.84% reported in 2018Q4 SEC filing. Fairfield Bush & Company acquired 347 shares as Amazon.Com Inc. (AMZN)’s stock rose 1.10%. The Fairfield Bush & Company holds 12,546 shares with $18.84M value, up from 12,199 last quarter. Amazon.Com Inc. now has $870.95B valuation. The stock increased 0.64% or $11.25 during the last trading session, reaching $1773.1. About 2.84M shares traded. Amazon.com, Inc. (NASDAQ:AMZN) has risen 13.57% since March 20, 2018 and is uptrending. It has outperformed by 9.20% the S&P500. Some Historical AMZN News: 02/04/2018 – Amazon also courted the online pharmacy start-up, the sources said; 23/03/2018 – The Dangerous Book for Boys, Amazon Prime – `wistful and charming comedy’; 26/04/2018 – Amazon’s sellers are going global, helping the company generate big profits; 19/04/2018 – Amazon’s Prime members are seen as fueling its apparel sales; 09/05/2018 – Amazon said in its quarterly report that AWS has at least $12.4 billion in backlog revenue, the first time its disclosed that metric; 14/05/2018 – Morgan Stanley Announces Amazon Alexa Skills – Offering Original Content and Market Insights Via Easy Voice Command; 21/05/2018 – Boston Wants Amazon, But Is There Room?; 12/04/2018 – Consumer Guru Michael Loeb Has a Plan to Fight Amazon (Video); 28/03/2018 – THERE ARE NO SPECIFIC POLICY CHANGES REGARDING AMAZON RIGHT NOW, BUT ALWAYS LOOKING AT DIFFERENT OPTIONS -WHITE HOUSE OFFICIAL; 17/04/2018 – New IRI Report Analyzes Impact of Amazon’s Acquisition of Whole Foods
Chemocentryx Inc (NASDAQ:CCXI) had a decrease of 17.4% in short interest. CCXI’s SI was 1.11M shares in March as released by FINRA. Its down 17.4% from 1.34M shares previously. With 407,200 avg volume, 3 days are for Chemocentryx Inc (NASDAQ:CCXI)’s short sellers to cover CCXI’s short positions. The SI to Chemocentryx Inc’s float is 4.64%. The stock decreased 2.63% or $0.3 during the last trading session, reaching $11.11. About 129,201 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since March 20, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress
More important recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates – Nasdaq” on March 11, 2019, also Nasdaq.com published article titled: “ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session – Nasdaq”, Nasdaq.com published: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” on March 11, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) was released by: Globenewswire.com and their article: “New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions â€” Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” with publication date: February 26, 2019.
Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 4 analyst reports since November 12, 2018 according to SRatingsIntel. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Buy” rating by Canaccord Genuity on Monday, November 12. The stock has “Buy” rating by H.C. Wainwright on Tuesday, March 12. Leerink Swann initiated the shares of CCXI in report on Thursday, February 14 with “Buy” rating.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $584.05 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
Since October 16, 2018, it had 0 insider buys, and 8 insider sales for $87.64 million activity. Schall Thomas J. sold $447,092 worth of stock or 36,762 shares. KANAYA SUSAN M sold $457,747 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, January 22. The insider Cappel Markus J. sold 30,237 shares worth $332,779. Another trade for 7.34M shares valued at $85.85M was sold by GLAXOSMITHKLINE PLC.
Investors sentiment decreased to 0.93 in Q4 2018. Its down 0.05, from 0.98 in 2018Q3. It turned negative, as 7 investors sold ChemoCentryx, Inc. shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Bank & Trust Of Mellon Corp owns 139,805 shares. Moreover, Zebra Cap Mngmt Limited Company has 0.1% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). American Interest Group Inc owns 14,790 shares. Sio Management Ltd Llc has invested 0.67% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Raymond James And Associate reported 0% stake. New York-based Ny State Common Retirement Fund has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Franklin Res reported 1.38 million shares. Dekabank Deutsche Girozentrale holds 0% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 16,500 shares. Landscape Cap Mgmt Limited stated it has 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Prns Ltd Liability Corporation owns 19,469 shares or 0.01% of their US portfolio. Paw Corp holds 0.68% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 50,000 shares. Strs Ohio owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 55,800 shares. California Public Employees Retirement System owns 67,452 shares or 0% of their US portfolio. 35,245 were reported by California State Teachers Retirement System. 324,223 were reported by Panagora Asset Inc.
More notable recent Amazon.com, Inc. (NASDAQ:AMZN) news were published by: Nasdaq.com which released: “EBAY vs. AMZN: Which Stock Should Value Investors Buy Now? – Nasdaq” on March 20, 2019, also Seekingalpha.com with their article: “PillPack gains licenses; Kindle gets upgrade – Seeking Alpha” published on March 20, 2019, Seekingalpha.com published: “Amazon launches skincare private label – Seeking Alpha” on March 20, 2019. More interesting news about Amazon.com, Inc. (NASDAQ:AMZN) were released by: Nasdaq.com and their article: “A Walmart Tablet Is Another Battle in Its War With Amazon – Nasdaq” published on March 20, 2019 as well as Nasdaq.com‘s news article titled: “Amazon (AMZN) Dips More Than Broader Markets: What You Should Know – Nasdaq” with publication date: March 14, 2019.
Since October 29, 2018, it had 0 insider buys, and 10 selling transactions for $50.29 million activity. 1,929 shares were sold by Zapolsky David, worth $3.02M on Thursday, November 15. Another trade for 2,055 shares valued at $3.22M was sold by Blackburn Jeffrey M. 1,375 shares valued at $2.31M were sold by STONESIFER PATRICIA Q on Friday, November 2. Jassy Andrew R sold $2.70M worth of stock or 1,726 shares. Olsavsky Brian T sold $3.21M worth of Amazon.com, Inc. (NASDAQ:AMZN) on Thursday, November 15. Reynolds Shelley sold 437 shares worth $687,447. On Thursday, November 15 Huttenlocher Daniel P sold $285,960 worth of Amazon.com, Inc. (NASDAQ:AMZN) or 181 shares.
Investors sentiment increased to 1.55 in Q4 2018. Its up 0.37, from 1.18 in 2018Q3. It is positive, as 93 investors sold AMZN shares while 536 reduced holdings. 184 funds opened positions while 793 raised stakes. 371.97 million shares or 42.70% more from 260.67 million shares in 2018Q3 were reported. Jacobson And Schmitt Advsr Limited Co accumulated 3,941 shares or 4.27% of the stock. Clark Group Inc Incorporated Inc owns 977 shares. Tiger Global Ltd Liability has 744,014 shares for 7.44% of their portfolio. Bristol John W Communications Incorporated New York reported 3.65% of its portfolio in Amazon.com, Inc. (NASDAQ:AMZN). Crystal Rock Cap Mngmt reported 2,380 shares. Pennsylvania has invested 0.73% in Amazon.com, Inc. (NASDAQ:AMZN). 9,409 are owned by Hollencrest Cap Mngmt. Capstone Financial Incorporated invested in 0.4% or 1,331 shares. Williams Jones & Assocs Ltd Liability invested in 2.03% or 49,940 shares. Freestone Cap Limited owns 0.94% invested in Amazon.com, Inc. (NASDAQ:AMZN) for 9,247 shares. New Mexico Educational Retirement Board has 2.49% invested in Amazon.com, Inc. (NASDAQ:AMZN) for 34,865 shares. Riverpark Cap Mngmt Limited Com, New York-based fund reported 16,077 shares. Natl Bank Of America De accumulated 3.17 million shares. Stoneridge Investment Prns Ltd Llc invested in 6,621 shares or 3.12% of the stock. Sabal Trust owns 0.03% invested in Amazon.com, Inc. (NASDAQ:AMZN) for 191 shares.
Among 13 analysts covering Amazon.com (NASDAQ:AMZN), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Amazon.com had 20 analyst reports since September 25, 2018 according to SRatingsIntel. The stock of Amazon.com, Inc. (NASDAQ:AMZN) earned “Buy” rating by Bank of America on Wednesday, November 28. Jefferies maintained Amazon.com, Inc. (NASDAQ:AMZN) on Tuesday, September 25 with “Buy” rating. The rating was maintained by Deutsche Bank with “Buy” on Wednesday, January 23. The rating was maintained by Raymond James on Friday, February 1 with “Outperform”. As per Thursday, February 28, the company rating was maintained by Morgan Stanley. UBS maintained Amazon.com, Inc. (NASDAQ:AMZN) on Monday, March 11 with “Buy” rating. The stock of Amazon.com, Inc. (NASDAQ:AMZN) has “Buy” rating given on Monday, March 18 by Wells Fargo. On Tuesday, March 19 the stock rating was maintained by Bank of America with “Buy”. Bank of America maintained Amazon.com, Inc. (NASDAQ:AMZN) rating on Friday, October 26. Bank of America has “Buy” rating and $2000 target. The stock of Amazon.com, Inc. (NASDAQ:AMZN) has “Overweight” rating given on Friday, March 15 by KeyBanc Capital Markets.